hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06271694 id: STUDY22020027 id: 1K23DC020215-01 type: NIH link: https://reporter.nih.gov/quickSearch/1K23DC020215-01 briefTitle: Activity and Participation in Vestibular Disorders acronym: APV overallStatus: RECRUITING date: 2024-01-01 date: 2024-11-29 date: 2025-01-31 date: 2024-02-22 date: 2024-04-25 name: University of Pittsburgh class: OTHER name: National Institute on Deafness and Other Communication Disorders (NIDCD) briefSummary: This study will examine whether impairments and personal factors are associated with activity and participation in people with vestibulopathy. Data collection will occur prior to starting vestibular rehabilitation and after completing vestibular rehabilitation. conditions: Vestibular Disorder studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 50 type: ESTIMATED name: Vestibular Rehabilitation measure: Late-life Function and Disability Instrument measure: Dizziness Handicap Inventory sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: UPMC-Rehab Institute status: RECRUITING city: Pittsburgh state: Pennsylvania zip: 15206 country: United States name: Chelsea Behling role: CONTACT phone: 412-624-8811 email: chb317@pitt.edu lat: 40.44062 lon: -79.99589 hasResults: False
nctId: NCT06271681 id: 2120135-1 briefTitle: Evaluation of PCV15 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2024-08-01 date: 2025-02-01 date: 2024-02-22 date: 2024-02-22 name: VA Sierra Nevada Health Care System class: FED name: Merck Sharp & Dohme LLC briefSummary: The investigators will evaluate the immune response of immunocompromised adults, who have previously received at least 1 dose of 23-valent pneumococcal polysaccharide vaccine, to the booster series of 15-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal polysaccharide vaccine 8 weeks later. Immune response will be assessed by opsonophagocytic assay reactivity and IgG Geometric mean concentration changes. conditions: Pneumococcal Vaccines conditions: Immunosuppression studyType: INTERVENTIONAL phases: PHASE4 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 45 type: ESTIMATED name: 15-valent pneumococcal conjugate vaccine name: 23-valent pneumococcal polysaccharide vaccine measure: Change in opsonophagocytic assay (OPA) geometric mean titers (GMT) measure: Change in Immunoglobulin G (IgG) geometric mean concentrations (GMC) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06271668 id: 23-2356 id: R61DA057610 type: NIH link: https://reporter.nih.gov/quickSearch/R61DA057610 briefTitle: Clinical Decision Support to Improve System Naloxone Co-prescribing overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2026-03 date: 2026-09 date: 2024-02-22 date: 2024-02-29 name: University of Colorado, Denver class: OTHER name: National Institutes of Health (NIH) name: National Institute on Drug Abuse (NIDA) briefSummary: The objective of this study is to evaluate the impact of a clinical decision support (CDS) alert to facilitate the co-prescribing of naloxone, an opioid overdose reversal agent, with high-risk opioid prescriptions. Prescribing naloxone with opioids is a best practice described in the 2022 US Center for Disease Control and Prevention (CDC) guidelines on opioid prescribing. The CDS can improve quality of care delivered by improving compliance with the guideline defined best practices. The project will compare CDS alert facilitated co-prescribing of naloxone with high-risk opioid prescriptions vs usual care to evaluate the effectiveness of the CDS alert for improving naloxone prescribing. The patients are not assigned to an intervention and will be receiving any changes in care as part of their routine medical care, rather than a specific intervention that is distinct from their usual medical care. The researchers hypothesize that the CDS alert will be acceptable to providers while increasing naloxone co-prescribing which will reduce the number of opioid overdoses in subsequent 6 months. conditions: Medication Abuse conditions: Harm Reduction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 200000 type: ESTIMATED name: Naloxone Co-prescribing Clinical Decision Support (CDS) measure: Percentage of a high-risk opioid analgesic prescriptions receiving a co-prescription of naloxone measure: Clinical decision support (CDS) acceptance rate measure: Subsequent opioid overdose/poisonings rates measure: Naloxone dispensed rate sex: ALL minimumAge: 12 Years maximumAge: 89 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado Hospital city: Aurora state: Colorado zip: 80045 country: United States lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06271655 id: BFD-RST-23-004 briefTitle: Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE) acronym: RADIATE overallStatus: RECRUITING date: 2024-03-12 date: 2024-09-30 date: 2024-09-30 date: 2024-02-22 date: 2024-04-09 name: Christopher Payette class: OTHER name: BioMérieux briefSummary: The study titled " The Effect of Definitive Identification of Viral Etiology in Emergency Department Patients with Acute Respiratory Infection on Antibiotic Utilization (RADIATE)" aims to investigate the effectiveness of a rapid diagnostic approach in reducing unnecessary antibiotic use in the emergency department (ED) for patients presenting with acute respiratory illness (ARI) due to a virus. Using a prospective design, eligible participants are individuals who visit the ED with complaints related to acute respiratory illness. The study will employ a single-arm consecutive enrollment approach. The intervention involves the implementation of a rapid point-of-care multiplex polymerase chain reaction (PCR) test to promptly identify the viral cause of the infection. By utilizing a rapid diagnostic tool to identify viral etiology, the study aims to provide healthcare professionals in the ED with more accurate information to guide treatment decisions. Ultimately, the goal is to decrease the unnecessary use of antibiotics for ARI's due to a virus, which has several negative outcomes including promotion of antibiotic resistance, exacerbating ED length of stay and encouraging unnecessary additional diagnostic tests. conditions: Acute Respiratory Infection conditions: Viral Infection conditions: Upper Respiratory Tract Infections studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 200 type: ESTIMATED name: SPOTFIRE R Panel measure: Antibiotic Use measure: Emergency Department Length of Stay measure: Utilization of Alternative Tests measure: Patient Confidence in Diagnosis measure: Provider Confidence in Diagnosis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: George Washington University Hospital status: RECRUITING city: Washington state: District of Columbia zip: 20037 country: United States name: Ryan Heidish role: CONTACT email: rheidish@mfa.gwu.edu name: Christopher Payette, MD role: CONTACT email: cpayette@mfa.gwu.edu name: Christopher Payette, MD role: PRINCIPAL_INVESTIGATOR name: Andrew Meltzer, MD, MS role: SUB_INVESTIGATOR lat: 38.89511 lon: -77.03637 hasResults: False
nctId: NCT06271642 id: 73822 briefTitle: Impact of Bluetooth Haptics Device Distraction on Mechanical Pain Thresholds Induced by PinPrick Stimulators overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2025-05-31 date: 2025-05-31 date: 2024-02-22 date: 2024-02-22 name: Stanford University class: OTHER briefSummary: This is a prospective, crossover study of healthy participants evaluating the mechanical pain threshold for weighted pinprick stimuli. conditions: Pain conditions: Anxiety studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 120 type: ESTIMATED name: Bluetooth Haptic Device (Experimental Frequency) + Needle Sham only name: Bluetooth Haptic Device (Control Frequency) + Needle Sham only measure: Mechanical Pain Threshold measure: Mechanical pain sensitivity measure: Anxiety scores sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06271629 id: 2204-042-1314 briefTitle: Impact of Quality of Life in the Patients With Sleep Disturbance From Low Anterior Resection Syndrome in Advanced Rectal Cancer Patients overallStatus: COMPLETED date: 2022-02-26 date: 2023-11-30 date: 2024-02-29 date: 2024-02-22 date: 2024-03-26 name: Seoul National University Hospital class: OTHER name: Ministry of Health, Republic of Korea briefSummary: The preservation surgery of the anal sphincter has become a standard procedure for the treatment of rectal cancer and is now possible even when the tumor is close to the anus, thanks to the advancement of surgical techniques. This procedure allows patients to avoid a permanent artificial anus and enables them to evacuate through the anus, maintaining the continuity of the intestine, making it a highly preferred surgical option. Additionally, advancements in tumor treatments have led to improved long-term survival rates.
However, this anal sphincter preservation surgery inevitably can cause functional abnormalities in the rectum, and around 90% of patients experience changes in bowel habits after surgery. The characteristic symptoms occurring after rectal cancer surgery, such as diarrhea, urgency of bowel movements, frequent bowel movements, and fecal incontinence, are referred to as Anterior Resection Syndrome (ARS). Particularly, symptoms following low anterior resection surgery for lower rectal cancer are termed Low Anterior Resection Syndrome (LARS). These symptoms are most severe immediately after surgery, persisting up to 1-2 years, with some improvement over time. However, in many patients, LARS can remain a lifelong challenge, significantly impacting their quality of life. Currently, there is no definitive method to treat LARS, and symptom management is achieved through empirical treatment methods or medications.
Many patients with LARS experience these symptoms predominantly at night, and it is presumed that their sleep quality is severely compromised, significantly affecting their overall quality of life. However, there is a lack of research on the prevalence of such patients and the appropriate treatments for them. conditions: Rectal Cancer conditions: Low Anterior Resection Syndrome conditions: Insomnia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 100 type: ACTUAL name: Insomnia severity index measure: Impairment in the quality of sleep and quality of life in patients with Low Anterior Resection Syndrome (LARS). measure: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) measure: European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-CR29) sex: ALL minimumAge: 19 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Seoul National University Hospital city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06271616 id: MC1873 id: NCI-2024-01061 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 18-008754 type: OTHER domain: Mayo Clinic Institutional Review Board briefTitle: Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-05-31 date: 2027-05-31 date: 2024-02-22 date: 2024-03-20 name: Mayo Clinic class: OTHER briefSummary: This phase II trial tests how well ibrutinib works in preventing chronic graft-versus-host disease (GVHD) in patients undergoing donor (allogeneic) hematopoietic cell transplantation (HCT). An allogeneic hematopoietic cell transplantation (allo-HCT) is a treatment in which a person receives blood-forming stem cells (cells from which all blood cells develop) from a genetically similar, but not identical donor. When healthy stem cells from a donor are infused into a patient, they may help the patient's bone marrow make more healthy cells and platelets. However, sometimes the transplanted cells from a donor can attack the body's normal cells (called GVHD). Giving ibrutinib after the transplant may stop that from happening. Ibrutinib is in a class of medications called kinase inhibitors. It works by blocking a protein in the blood called Bruton's tyrosine kinase (BTK). By blocking BTK, ibrutinib inhibits certain immune cells that play a role in cGVHD. Giving ibrutinib after an allo-HCT may prevent the development of chronic GVHD. conditions: Chronic Graft Versus Host Disease conditions: Hematopoietic and Lymphatic System Neoplasm studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 40 type: ESTIMATED name: Biospecimen Collection name: Echocardiography name: Ibrutinib measure: Cumulative incidence of NIH moderate/severe chronic graft-versus-host disease (GVHD) measure: Cumulative incidence of non-relapse mortality (NRM) measure: Cumulative incidence of relapse measure: Cumulative incidence of moderate/severe chronic GVHD measure: Cumulative incidence of moderate/severe chronic GVHD measure: Cumulative incidence of chronic GVHD of all grades measure: Cumulative incidence of late acute GVHD measure: Overall survival (OS) measure: NIH moderate/severe GVHD and relapse free survival (CRFS) measure: Type and duration of immune suppressive therapy measure: Cumulative incidence of complete immune suppression (IS) discontinuation measure: Incidence of adverse events (AE) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mayo Clinic in Florida city: Jacksonville state: Florida zip: 32224-9980 country: United States name: Clinical Trials Referral Office role: CONTACT phone: 855-776-0015 email: mayocliniccancerstudies@mayo.edu name: Mohamed A. Kharfan Dabaja, M.D., M.B.A. role: PRINCIPAL_INVESTIGATOR lat: 30.33218 lon: -81.65565 hasResults: False
nctId: NCT06271603 id: 23.02645.000357-MS01 id: CPP Ile de France III type: OTHER domain: 23.02645.000357-MS01 briefTitle: Evaluation of the Efficiency and Economic Impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the Diagnosis and Management of Basal Cell Carcinomas acronym: ECOBASO overallStatus: NOT_YET_RECRUITING date: 2024-02-26 date: 2026-02 date: 2026-02 date: 2024-02-22 date: 2024-02-22 name: Damae Medical class: INDUSTRY briefSummary: This is a comparative, randomized, prospective, multicenter clinical investigation aimed at evaluating the efficiency and economic impact of LC-OCT (Line-field Confocal Optical Coherence Tomography) for the diagnosis and management of basal cell carcinomas. conditions: Basal Cell Carcinoma of the Skin studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: DIAGNOSTIC masking: NONE count: 704 type: ESTIMATED name: diagnosis based on deepLive™ LC-OCT device name: diagnosis based on skin biopsy measure: The primary objective is to demonstrate, at 1 year, the clinical non-inferiority and organizational and economic superiority of the management of primary BCC through diagnosis with LC-OCT compared to traditional management. measure: The primary objective is to demonstrate, at 1 year, the clinical non-inferiority and organizational and economic superiority of the management of primary BCC through diagnosis with LC-OCT compared to traditional management. measure: The primary objective is to demonstrate, at 1 year, the clinical non-inferiority and organizational and economic superiority of the management of primary BCC through diagnosis with LC-OCT compared to traditional management. measure: Compare, after the diagnosis announcement and at 1 year, the quality of life of patients in the LC-OCT arm versus the standard management arm. measure: Compare, after the diagnosis announcement and at 1 year, the anxiety levels of patients in the LC-OCT arm versus the standard management arm. measure: Compare patient satisfaction with their management at 1 year in the LC-OCT arm versus the standard management arm. measure: Evaluate the performance of LC-OCT for the diagnosis and subtyping of BCC for all patients operated on or biopsied in the LC-OCT arm. measure: Compare dermatologists' satisfaction with patient management in the LC-OCT arm versus the standard management arm measure: Estimate the actual cost of conducting the diagnosis with LC-OCT technology. measure: Compare healthcare consumption between the two groups at 1 year. measure: Conduct a cost-consequence analysis of patient management with LC-OCT technology versus standard management. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital Ambroise Paré city: Boulogne-Billancourt zip: 92100 country: France name: Professeur Philippe SAIAG role: CONTACT phone: 800-555-5555 email: philippe.saiag@uvsq.fr name: Philippe SAIAG role: PRINCIPAL_INVESTIGATOR lat: 48.83333 lon: 2.25 hasResults: False
nctId: NCT06271590 id: CM-US-R03 briefTitle: MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels acronym: MAGICAL-SV overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-04 date: 2031-04 date: 2024-02-22 date: 2024-02-22 name: Concept Medical Inc. class: INDUSTRY name: Cardiovascular Research Foundation, New York briefSummary: This is a multicenter, randomized, single-blind pivotal study to evaluate the safety and efficacy of the MagicTouchTM Drug coated balloon in treatment of small vessels in patients with coronary artery disease. The objective is to establish the safety and efficacy of the Magic TouchTM Drug coated balloon in treatment of small vessels (≤2.75 mm).
A total of 1605 subjects will be enrolled in a maximum of 50 study sites located in North America. Additional sites located in Europe and South America may also participate in the study, with non-US sites contributing a maximum of \~50% of enrollees. conditions: Coronary Artery Disease conditions: Native Coronary Artery Stenosis conditions: Cardiovascular Diseases studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 2:1 randomized trial (MagicTouchTM Sirolimus-Coated Balloon VS Drug eluting stent (ZES or EES) primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 1605 type: ESTIMATED name: Sirolimus Drug Coated Balloon name: Drug eluting stents (DES) measure: Target lesion failure (TLF) measure: Procedural success measure: Target lesion failure (TLF) measure: Ischemia driven target vessel revascularization (ID-TVR) measure: Target vessel revascularization (TVR) measure: Any revascularization measure: Target vessel failure (TVF) measure: Q-wave myocardial infarction (MI) measure: Non Q-wave myocardial infarction (MI) measure: Any myocardial infarction (MI) measure: Target vessel myocardial infarction (TV MI) measure: Spontaneous myocardial infarction (MI) measure: Procedural myocardial infarction (MI) measure: Cardiovascular mortality measure: All-cause mortality measure: Cardiovascular mortality or myocardial infarction (MI) measure: All-cause mortality or MI measure: All-cause mortality, myocardial infarction (MI) or target vessel revascularization (TVR) measure: Any probable or definite stent thrombosis measure: Probable stent thrombosis measure: Definite stent thrombosis measure: Angina as assessed by SAQ-7 (Seattle Angina Questionnaire) sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06271577 id: PRO-0013 briefTitle: Smartphone Twelve-Lead ECG Utility In ST-Elevation Myocardial Infarction II acronym: STLEUISII overallStatus: RECRUITING date: 2024-03-12 date: 2024-11 date: 2024-12 date: 2024-02-22 date: 2024-03-19 name: AliveCor class: INDUSTRY briefSummary: AliveCor (www.alivecor.com) has developed several electrocardiogram (ECG) devices that interface with iOS and Android smartphones and tablets via various Kardia apps. The current Kardia family of devices can measure single lead and six limb-lead ECGs, depending on the device. KardiaMobile, KardiaMobile 6L, and KardiaMobile Card have FDA clearance for ECG rhythm recording. A modified single-lead Kardia smartphone 12-lead ECG was previously validated in the multicenter ST LEUIS study for the diagnosis of ST-Segment Elevation Myocardial Infarction (STEMI) and Non-ST-Elevation Myocardial Infarction (NSTEMI).
nctId: NCT06271564 id: FDASU-Rec IM012415 briefTitle: Effectiveness of Topical Magnetite Zinc Oxide Composite Nanoparticles in the Management of Oral Potentially Malignant Lesions overallStatus: RECRUITING date: 2024-02-29 date: 2024-07 date: 2024-12 date: 2024-02-22 date: 2024-03-05 name: Ain Shams University class: OTHER briefSummary: ZnO nanoparticles are now being widely researched for their anticancer properties. They show relatively high biocompatibility. They also show selective cytotoxicity against cancerous cells in in vitro condition compared with other nanoparticles. They can be further surface engineered to show increased selective cytotoxicity. The synthesis process of ZnO nanoparticles is relatively easy, with a wide variety of methods. Owing to these different methods of synthesis, their size and size distribution can be easily controlled. One of the novel methods of synthesis of ZnO is Magnetite ZnO-Fe3O4 Composite Nanoparticles.Magnetite ZnO-Fe3O4 conjugated NPs retained inherent selective property of ZnO and magnetic property of Fe3O4 NPs and showed preferential cytotoxicity towards breast cancer cell line MDA-MB-231, with no significant cytotoxicity towards noncancerous Mouse Fibroblast NIH 3T3 cell. conditions: Oral Potentially Malignant Lesions studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 20 type: ESTIMATED name: Magnetite ZnO Composite Nanoparticles name: Topical Placebo Gel measure: Change in the clinical size in Low to Moderate Dysplastic OPLs using Magnetite ZnO-Fe3O4 Composite NPs using standardized photographs of the oral marker lesion for each patient measure: Effect of Magnetite ZnO-Fe3O4 Composite NPs on the change of the degree of Dysplasia during histopathological examination using a biopsy sex: ALL minimumAge: 25 Years maximumAge: 60 Years stdAges: ADULT facility: Faculty of Dentistry Ain shams University status: RECRUITING city: Cairo country: Egypt name: Nourhane Omara, Master's role: CONTACT lat: 30.06263 lon: 31.24967 hasResults: False
nctId: NCT06271551 id: ESTRACISE briefTitle: Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy acronym: ESTRACISE overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2028-12 date: 2029-12 date: 2024-02-21 date: 2024-02-21 name: Central Finland Hospital District class: OTHER name: Tampere University name: University of Jyvaskyla name: Tampere University Hospital briefSummary: The goal of the clinical trial is to find out whether transdermal estradiol will reduce the adverse effects of androgen deprivation therapy in prostate cancer patients.